Get started
Author

Shanti Amé

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
2010 · Raphael Itzykson, Sylvain Thépot, et al. · Blood · 384
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group
2018 · Delphine Rea, Shanti Ame, et al. · Cancer · 75
PDF
Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation
2016 · Jean Claude Chomel, Marie Laure Bonnet, et al. · Oncotarget · 64
PDF
Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study
2015 · Franck E Nicolini, Gabriel Etienne, et al. · The Lancet Haematology · 54
High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM
2013 · C. Kelaidi, O. Beyne-Rauzy, et al. · Annals of Hematology · 48
Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study
2018 · Maël Heiblig, Delphine Rea, et al. · Experimental Hematology · 45
New Data on the Epidemiology of Breast Implant- Associated Anaplastic Large Cell Lymphoma
2021 · Paul Ionescu, Florence Vibert, et al. · European Journal of Breast Health · 35
PDF
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
2020 · Marlijn Hoeks, Tim Bagguley, et al. · Leukemia · 27
PDF
Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia
2020 · Rémi Letestu, Abdelmalek Dahmani, et al. · Leukemia · 27
A randomised phase II study of azacitidine ( AZA ) alone or with Lenalidomide ( LEN ), Valproic acid ( VPA ) or Idarubicin ( IDA ) in higher‐Risk MDS or low blast AML : GFM 's “pick a winner” trial, with the impact of somatic mutations
2022 · Lionel Adès, Nicolas Duployez, et al. · British Journal of Haematology · 21
Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes
2013 · Thomas Prebet, Thorsten Braun, et al. · Leukemia Research · 18
Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial
2021 · Franck E. Nicolini, Gabriel Etienne, et al. · Blood · 16
Breast Cancer Management During the COVID-19 Pandemic: The Senologic International Society Survey
2021 · Carole Mathelin, Shanti Ame, et al. · European Journal of Breast Health · 15
PDF
The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.
2019 · Franck E Nicolini, Gabriel Etienne, et al. · Blood · 15
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?
2011 · R. Itzykson, S. Thépot, et al. · Leukemia Research · 15
Dasatinib plus Peg‐Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study ( DASA‐PegIFN study)
2022 · Lydia Roy, Jean‐Claude Chomel, et al. · British Journal of Haematology · 13
Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)
2015 · Lydia ROY, Jean-Claude Chomel, et al. · Blood · 13
Azacitidine improves outcome in higher‐risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries
2018 · María Díez‐Campelo, Jose I. Lorenzo, et al. · British Journal of Haematology · 12
PDF
Recommandations 2015 du France Intergroupe des Leucémies Myéloïdes Chroniques pour la gestion du risque d’événements cardiovasculaires sous nilotinib au cours de la leucémie myéloïde chronique
2016 · Delphine Rea, Shanti Ame, et al. · Bulletin du Cancer · 10
Prospective evaluation of the effect of deferasirox on hematologic response in transfusion‐dependent patients with low‐risk MDS and iron overload
2018 · Christian Rose, Caroline Lenoir, et al. · European Journal Of Haematology · 9
Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial
2017 · Franck Emmanuel Nicolini, Gabriel Etienne, et al. · Blood · 8
Prolonged Survival without Complete Remission (CR) In AML Patients (Pts) Treated with Azacitidine (AZA)
2010 · Raphael Itzykson, Sylvain Thepot, et al. · Blood · 8
Protective role of melatonin in breast cancer: what we can learn from women with blindness
2021 · Chris Minella, Pierre Coliat, et al. · Cancer Causes & Control · 7
Pegylated Interferon-α 2a in Combination to Nilotinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Provides High Rates of MR4.5. Preliminary Results of a Phase II Study.
2012 · Franck E. Nicolini, Gabriel Etienne, et al. · Blood · 7
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia
2023 · Marie Balsat, Vincent Alcazer, et al. · Leukemia Research · 5
Works count: 59
Citation count: 979
H-index: 15
I10-index: 19
Year
Topic
Type